US Patent Office Issues Patent for USMI’s Cold Atmospheric Plasma for the Treatment of Cancer

TAKOMA PARK, Md.–(BUSINESS WIRE)–#CAPkillscancerUS
Medical Innovations, LLC (USMI)
, a U.S. FDA registered life
science and biomedical device company, and subsidiary of US Patent
Innovations, LLC (USPI), announced today that the United States Patent
Office (USPO) is issuing to the company Patent No. 9,999.452 for their
Cold Atmospheric Plasma (CAP) technology “Integrated Cold Plasma and
High Frequency Plasma Electrosurgical System and Method” for use in the
treatment of cancer therapy.

USMI is the first company in the world to integrate a high frequency
electrosurgical generator and plasma gas to deliver a Cold Atmospheric
Plasma (CAP) for the selective treatment of cancer. This novel process
for using CAP technology is being developed for use during surgery. It
has been reported that CAP selectively ablates cancer cells without
damaging healthy human tissue. The CAP effect has shown to cause
significant stress to cancer cells that drastically decreases the cell’s
viability, while healthy human cells remain unharmed.

Utilizing USMI’s patented electrosurgical plasma system, CAP is
delivered through the Canady Helios™ Plasma Scalpel. This new technology
was developed by Dr. Jerome Canady and his team at the Jerome Canady
Research Institute for Advanced Biological and Technological Sciences
(JCRI/ABTS) in conjunction with Michael Keidar PhD, Director of George
Washington University’s (GWU) and USMI Plasma Medicine Program, Alex
Shashurin, PhD, Purdue University and Taisen Zhuang, PhD VP Research &
Development USMI.

Dr. Michael Keidar said, “this approach allows removal of tumor and
treatment of surgical margins for ablating cancer cells using a single
device.” Dr. Keidar added that a multi-institutional clinical trial will
start this summer.

Jerome Canady, M.D., CEO at USMI, and Co-Director of the GWU Plasma
Medicine Program commented, “After the surgeon removes the cancerous
tumor, CAP is subsequently sprayed at the surgical margins to ablate any
remaining cancerous tissue or cells, thus reducing the chances of cancer
recurrence. We see our CAP treatment as an important adjunct to the
current treatment protocol for solid cancerous tumors. Our new plasma
devices will change the landscape of electrosurgery and cancer therapy
as well as offer cancer patients new hope in the very near-future.”

About US Medical Innovations

US Medical Innovations, LLC (USMI), based out of Takoma Park, MD, is a
privately-held FDA registered life science and biomedical device
company. USMI is dedicated to expanding the boundaries of plasma
medicine by pioneering new technologies for the development of
state-of-the-art medical devices that advance patient outcomes and
improve human lives. Leveraging the insights of USMI’s CEO and
Co-Founder, as both a transplant surgeon and inventor, Dr. Canady
continues to transition USMI to a Life Science company by investing its
R&D in cancer therapies and robotics. For more information on US Medical
Innovation’s products and technology please visit: USMEDINNOVATIONS.com

Contacts

US Medical Innovations, LLC
Kenniah Chestnut, Esq.
301-270-0147
KChestnut@usmedinnov.com
www.usmedinnovations.com